Skip to content

MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511626-30-00
Acronym
MEMENTO
Enrollment
14
Registered
2024-08-05
Start date
2025-03-09
Completion date
Unknown
Last updated
2025-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophageal adenocarcinoma

Brief summary

Metabolic switch in macrophages measured by M2 to M1 macrophage polarization within the tumour immune microenvironment and the number of CD8 intratumoral T-cell infiltration determined with single cell mRNA sequencing.

Detailed description

Measure changes in T cell infiltration and the CD3:CD163 ratio within the spatial context by multicolor immunohistochemistry (mIHC)., Detect metabolic changes in macrophages and T cells in the tumour immune microenvi-ronment by SCENITH flow cytometry analysis., Pathological response according to pTNM stage and Mandard criteria, Adverse events based on Common Toxicity Criteria for Adverse Events (CTCAE)., Progression free survival, Overall survival

Interventions

DRUGMetformin Aurobindo 500 mg film-coated tablets

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Metabolic switch in macrophages measured by M2 to M1 macrophage polarization within the tumour immune microenvironment and the number of CD8 intratumoral T-cell infiltration determined with single cell mRNA sequencing.

Secondary

MeasureTime frame
Measure changes in T cell infiltration and the CD3:CD163 ratio within the spatial context by multicolor immunohistochemistry (mIHC)., Detect metabolic changes in macrophages and T cells in the tumour immune microenvi-ronment by SCENITH flow cytometry analysis., Pathological response according to pTNM stage and Mandard criteria, Adverse events based on Common Toxicity Criteria for Adverse Events (CTCAE)., Progression free survival, Overall survival

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026